Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
50
CNTX Quote, Financials, Valuation and Earnings
Last price:
$1.27
Seasonality move
:
-30%
Day range:
$1.16 - $1.30
52-week range:
$0.49 - $1.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.59x
Volume:
901.3K
Avg. volume:
553.6K
1-year change:
16.51%
Market cap:
$116.7M
Revenue:
--
EPS (TTM):
-$0.28
Analysts' Opinion
-
Consensus RatingContext Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.33, Context Therapeutics, Inc. has an estimated upside of 319.95% from its current price of $1.27.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $1.27.
Fair Value
-
According to the consensus of 5 analysts, Context Therapeutics, Inc. has 319.95% upside to fair value with a price target of $5.33 per share.
CNTX vs. S&P 500
-
Over the past 5 trading days, Context Therapeutics, Inc. has overperformed the S&P 500 by 21.99% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Context Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Context Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Context Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Context Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Context Therapeutics, Inc. reported earnings per share of -$0.10.
Enterprise value:
39.9M
EV / Invested capital:
0.54x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.78x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$40.4K
Return On Assets:
-29.79%
Net Income Margin (TTM):
--
Return On Equity:
-31.05%
Return On Invested Capital:
-30.98%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$12.7K | -$10.5K | -$40.4K | -$2.8K | -$4.1K | |
| Operating Income | -$22M | -$32.5M | -$30.2M | -$18.7M | -$10.6M | |
| EBITDA | -$22M | -$32.5M | -$30.2M | -$18.7M | -$10.6M | |
| Diluted EPS | -$1.30 | -$0.91 | -$0.28 | -$0.22 | -$0.10 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $437.5K | $41.9M | $23M | $86.1M | $78.9M | |
| Total Assets | $2.3M | $42.1M | $23M | $86.3M | $79.2M | |
| Current Liabilities | $4.4M | $4M | $4.6M | $2.3M | $6M | |
| Total Liabilities | $4.4M | $4M | $4.6M | $2.5M | $6.1M | |
| Total Equity | -$2.1M | $38.1M | $18.4M | $83.9M | $73.2M | |
| Total Debt | -- | -- | -- | $140.2K | $21.2K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$17.8M | -$16.9M | -$22.3M | -$1.9M | -$6.6M | |
| Cash From Investing | -- | -$14.8M | -$33.9K | -$14.8M | -- | |
| Cash From Financing | -- | $94.8M | $14.5M | -$44.6K | -- | |
| Free Cash Flow | -$18.3M | -$31.6M | -$22.4M | -$16.7M | -$6.6M | |
CNTX
Sector
Market Cap
$116.7M
$27.9M
Price % of 52-Week High
81.94%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-16.34%
-1.49%
1-Year Price Total Return
16.51%
-16.66%
Beta (5-Year)
--
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.12
200-day SMA
Buy
Level
$0.88
Bollinger Bands (100)
Buy
Level
0.83 - 1.21
Chaikin Money Flow
Sell
Level
-175.7M
20-day SMA
Buy
Level
$1.10
Relative Strength Index (RSI14)
Buy
Level
64.95
ADX Line
Buy
Level
16.78
Williams %R
Sell
Level
-9.8344
50-day SMA
Buy
Level
$1.17
MACD (12, 26)
Sell
Level
0.01
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
214.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (18.5591)
Sell
CA Score
(Annual)
Level (-0.8165)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (15.5059)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.
Stock Forecast FAQ
In the current month, CNTX has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CNTX average analyst price target in the past 3 months is $5.33.
-
Where Will Context Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Context Therapeutics, Inc. share price will rise to $5.33 per share over the next 12 months.
-
What Do Analysts Say About Context Therapeutics, Inc.?
Analysts are divided on their view about Context Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Context Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Context Therapeutics, Inc.'s Price Target?
The price target for Context Therapeutics, Inc. over the next 1-year time period is forecast to be $5.33 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CNTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Context Therapeutics, Inc. is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CNTX?
You can purchase shares of Context Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Context Therapeutics, Inc. shares.
-
What Is The Context Therapeutics, Inc. Share Price Today?
Context Therapeutics, Inc. was last trading at $1.27 per share. This represents the most recent stock quote for Context Therapeutics, Inc.. Yesterday, Context Therapeutics, Inc. closed at $1.27 per share.
-
How To Buy Context Therapeutics, Inc. Stock Online?
In order to purchase Context Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CNTX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CNTX
Sector
P/E ratio
--
23.85x
PEG ratio
--
-0.01x
P/B ratio
1.59x
1.81x
Price / LTM sales
--
1.58x
Growth Metrics
CNTX
Sector
Revenue growth
--
4.62%
Earnings growth
53.07%
10.5%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.09
-$0.21
Profitability
CNTX
Sector
Profitability FY 2024
-$52.7K
$3.6M
Return on invested capital
-30.98%
-31.87%
Return on assets
-29.79%
-28.18%
Return on equity
-31.05%
-37.63%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Dec
22
Estimated Next Earnings Date
Mar
23
Balance Sheet
CNTX
Sector
Total cash
$76.9M
$26.4M
Short term investments
--
$25.7M
Total assets
$98.1M
$76.9M
Long term debt
$21.2K
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
